Nearly 80% of people diagnosed with osteosarcoma start with localized disease, yet survival hinges on details like tumor necrosis and margin status that can swing outcomes dramatically. From SEER coverage spanning about 48% of the US population to PET specificities hovering around the 70% range, these statistics connect pathology and imaging to real clinical decision points. We pull together the most useful trial and biomarker measures, including the MAP backbone benchmark with reported 5 year overall survival of 70%, to show where osteosarcoma care succeeds and where it still struggles.
Key Takeaways
- Approximately 80% of patients with osteosarcoma present with localized disease at diagnosis
- The Surveillance, Epidemiology, and End Results (SEER) Program covers approximately 48% of the U.S. population
- In a large retrospective analysis, the 5-year overall survival differed substantially by metastatic status at diagnosis (localized vs metastatic)
- In osteosarcoma pathology, osteoid production by tumor cells is a defining microscopic feature used in diagnosis
- ATRX/DAXX pathway alterations have been noted in osteosarcoma molecular characterization efforts (as detailed in integrative genomic reports)
- Plasma alkaline phosphatase (ALP) is commonly measured clinically in osteosarcoma; ALP is used as a marker of bone turnover and disease burden in practice
- In clinical trials, event-free survival (EFS) is frequently reported with osteosarcoma regimens to capture time to progression or recurrence
- For patients with resectable extremity osteosarcoma, surgery with limb-salvage is common and is associated with better functional outcomes than amputation in modern cohorts
- In MAPS (metastatic) and other studies, complete surgical resection of metastases is associated with improved survival compared with incomplete resection
- In a 2017–2020 review of targeted therapy, multiple signaling pathway inhibitors were investigated for osteosarcoma, reflecting trial activity across PI3K/mTOR, TK, and other pathways
- Clinical trials for osteosarcoma are frequently listed in ClinicalTrials.gov; by 2024, there were hundreds of active entries for osteosarcoma overall
- ClinicalTrials.gov reports standardized data elements; trial records include study type, phase, recruitment status, and outcomes used to monitor osteosarcoma research activity
- In the EURAMOS-1 trial, 5-year overall survival (OS) was reported as 70% for patients receiving the standard methotrexate, doxorubicin, cisplatin (MAP) backbone regimen (reported study outcome)
- In a registry analysis comparing standard neoadjuvant chemotherapy, MAP-based regimens are most commonly used in osteosarcoma practice in Europe, with multi-agent chemotherapy constituting the majority of first-line treatments (proportions reported in utilization tables)
- In the same pooled analysis, FDG-PET/CT specificity for metastasis detection in osteosarcoma was reported in the ~70% range (pooled estimate reported)
Most osteosarcoma is localized at diagnosis, and surgery plus multi agent chemotherapy with complete resection improves survival.
Related reading
01 · Category
Epidemiology5 stats
01
Approximately 80% of patients with osteosarcoma present with localized disease at diagnosis
02
The Surveillance, Epidemiology, and End Results (SEER) Program covers approximately 48% of the U.S. population
03
In a large retrospective analysis, the 5-year overall survival differed substantially by metastatic status at diagnosis (localized vs metastatic)
04
In osteosarcoma, pathologic fracture at presentation is associated with worse outcomes in multiple cohorts; published analyses report statistically significant associations
05
A 2019 Global Cancer Observatory dataset provides country-level estimates for 'Bone' cancer incidence and mortality; the dataset includes osteosarcoma-relevant 'bone' categories with explicit counts (table-driven estimates)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, most osteosarcoma cases are diagnosed while still localized about 80%, but the gap in outcomes is driven by metastatic status at diagnosis and strengthened by other adverse presentation factors like pathologic fracture, underscoring how stage at presentation shapes the real-world burden even when surveillance systems like SEER cover about 48% of the US population.
02 · Category
Biomarkers6 stats
01
In osteosarcoma pathology, osteoid production by tumor cells is a defining microscopic feature used in diagnosis
02
ATRX/DAXX pathway alterations have been noted in osteosarcoma molecular characterization efforts (as detailed in integrative genomic reports)
03
Plasma alkaline phosphatase (ALP) is commonly measured clinically in osteosarcoma; ALP is used as a marker of bone turnover and disease burden in practice
04
Inflammatory markers such as CRP and LDH are reported in studies as prognostic indicators in bone sarcomas including osteosarcoma
05
MicroRNA and circulating biomarker studies are active in osteosarcoma research; a review documents reported associations with survival and response
06
In a review, tumor necrosis grading after preoperative chemotherapy is summarized with clinically used categories and thresholds
Interpretation
Biomarkers Interpretation
Across osteosarcoma biomarker research, clinicians already rely on plasma alkaline phosphatase and inflammatory markers like CRP and LDH while molecular studies highlight key alterations such as ATRX/DAXX pathway changes, and ongoing microRNA and circulating biomarker work continues to build on these measurable signals for prognosis and treatment response.
03 · Category
Treatment Landscape12 stats
01
In clinical trials, event-free survival (EFS) is frequently reported with osteosarcoma regimens to capture time to progression or recurrence
02
For patients with resectable extremity osteosarcoma, surgery with limb-salvage is common and is associated with better functional outcomes than amputation in modern cohorts
03
In MAPS (metastatic) and other studies, complete surgical resection of metastases is associated with improved survival compared with incomplete resection
04
A landmark meta-analysis reported that multi-agent chemotherapy improves survival in osteosarcoma compared with historical surgery alone
05
The EURAMOS-1 trial evaluated osteosarcoma outcomes in response-adapted settings based on histologic necrosis thresholds
06
MRI is the imaging modality of choice for local staging and surgical planning for extremity osteosarcoma
07
In a cohort report, limb-salvage surgery achieved local control rates comparable to historical amputation outcomes in many patients
08
A systematic review estimated that radiographic response and surgical margins are prognostic factors in osteosarcoma outcomes
09
A 2021 systematic review summarized evidence that neoadjuvant chemotherapy yields tumor necrosis measurable at surgery for risk stratification
10
FDG-PET/CT is commonly used for detecting metastatic disease and assessing response in osteosarcoma clinical settings
11
In osteosarcoma, surgical margin status is prognostic; inadequate margins are associated with higher local recurrence risk in clinical studies
12
Complete tumor resection combined with effective chemotherapy is associated with improved survival compared with incomplete resection in observational studies
Interpretation
Treatment Landscape Interpretation
Across the treatment landscape for osteosarcoma, the evidence consistently points to a combined strategy where modern limb-salvage surgery and complete metastasis resection improve outcomes, and multi agent chemotherapy remains a key driver of better survival compared with older surgery alone, with trials frequently tracking event-free survival as a measure of how long these benefits last.
04 · Category
Industry Trends5 stats
01
In a 2017–2020 review of targeted therapy, multiple signaling pathway inhibitors were investigated for osteosarcoma, reflecting trial activity across PI3K/mTOR, TK, and other pathways
02
Clinical trials for osteosarcoma are frequently listed in ClinicalTrials.gov; by 2024, there were hundreds of active entries for osteosarcoma overall
03
ClinicalTrials.gov reports standardized data elements; trial records include study type, phase, recruitment status, and outcomes used to monitor osteosarcoma research activity
04
The TARGET data portal provided downloadable osteosarcoma sequencing data and clinical annotations to support discovery research
05
The AACR Project GENIE/GENIE portal supports cancer genomic data access; such datasets are used in sarcoma studies including osteosarcoma
Interpretation
Industry Trends Interpretation
Industry trends in osteosarcoma research show strong momentum as multiple signaling pathway inhibitors were actively explored in 2017 to 2020 and by 2024 ClinicalTrials.gov listed hundreds of active osteosarcoma entries, supported by standardized trial reporting and major sequencing resources like TARGET and GENIE that together accelerate discovery.
05 · Category
Clinical Practice2 stats
01
In the EURAMOS-1 trial, 5-year overall survival (OS) was reported as 70% for patients receiving the standard methotrexate, doxorubicin, cisplatin (MAP) backbone regimen (reported study outcome)
02
In a registry analysis comparing standard neoadjuvant chemotherapy, MAP-based regimens are most commonly used in osteosarcoma practice in Europe, with multi-agent chemotherapy constituting the majority of first-line treatments (proportions reported in utilization tables)
Interpretation
Clinical Practice Interpretation
In everyday osteosarcoma clinical practice in Europe, multi agent MAP based first line neoadjuvant chemotherapy is the norm, and the EURAMOS 1 trial shows this standard approach yields a 70% 5 year overall survival.
More related reading
06 · Category
Diagnostics & Imaging1 stats
01
In the same pooled analysis, FDG-PET/CT specificity for metastasis detection in osteosarcoma was reported in the ~70% range (pooled estimate reported)
Interpretation
Diagnostics & Imaging Interpretation
For Diagnostics and Imaging, FDG PET CT shows only moderate specificity for metastasis detection in osteosarcoma with pooled specificity hovering around the 70% range, indicating a meaningful chance of false positives when imaging for spread.
07 · Category
Prognostic Factors3 stats
01
In a population-based analysis of pathology, tumor necrosis following preoperative chemotherapy is used to risk-stratify outcomes, and categories of poor vs good necrosis show materially different survival rates (necrosis threshold survival separation reported)
02
A systematic review of osteosarcoma prognostic factors reported that patients with <90% tumor necrosis after neoadjuvant chemotherapy have significantly worse survival than those with ≥90% necrosis (threshold effect reported)
03
A meta-analysis of resected metastases in osteosarcoma reported that complete (R0) metastasectomy is associated with improved survival compared with incomplete resection; the review reported hazard ratios for OS favoring complete resection (HR reported)
Interpretation
Prognostic Factors Interpretation
Across prognostic factor studies in osteosarcoma, achieving at least 90% tumor necrosis after neoadjuvant chemotherapy and obtaining complete R0 resection of resected metastases are associated with materially better survival, with the clearest threshold signal at <90% necrosis and improved overall survival when metastasectomy is complete rather than incomplete.
08 · Category
Biomarkers & Risk2 stats
01
In a multicenter retrospective study, axillary/bone turnover marker alkaline phosphatase (ALP) stratification showed that higher ALP levels correlate with worse progression-free survival; the study reported median PFS differences by ALP quartiles
02
In a cohort study evaluating inflammatory biomarkers in osteosarcoma, pretreatment lactate dehydrogenase (LDH) levels were associated with overall survival; the study reported a significant hazard ratio for high vs low LDH groups
Interpretation
Biomarkers & Risk Interpretation
Across osteosarcoma studies, biomarkers track risk in a clinically meaningful way, with higher alkaline phosphatase levels tied to worse progression-free survival by ALP quartile and pretreatment lactate dehydrogenase showing a significant overall survival hazard difference between high and low groups.
09 · Category
Market & Access2 stats
01
In a real-world database analysis of sarcoma treatment pathways, chemotherapy was administered as part of the initial treatment sequence in the majority of high-grade osteosarcoma patients; the utilization proportion was reported as >70% (percentage reported)
02
In a global cancer burden report by WHO, bone cancer contributes a small fraction of total malignancies; the report provides an estimate of new cases and deaths for malignant bone tumors (including osteosarcoma) with measurable counts (year-specific numbers shown)
Interpretation
Market & Access Interpretation
From a market and access perspective, the real-world data showing chemotherapy given in more than 70% of high-grade osteosarcoma patients early in treatment suggests strong reliance on timely, pathway-access to systemic therapy, even though WHO data indicate malignant bone tumors like osteosarcoma make up only a small slice of overall cancer burden.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Engström. (2026, February 13). Osteosarcoma Statistics. Gitnux. https://gitnux.org/osteosarcoma-statistics
MLA
Marcus Engström. "Osteosarcoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/osteosarcoma-statistics.
Chicago
Marcus Engström. 2026. "Osteosarcoma Statistics." Gitnux. https://gitnux.org/osteosarcoma-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)